搜尋結果
China is trying to solve school bullying, but is it ready to face the causes?
South China Morning Post· 22 小時前In the eyes of some, the problem may have stemmed from familiar challenges in China. ...
TTC AgriS International Partners Day 2024: Global cooperation for a future of sustainable ...
Bastillepost· 22 小時前NODSOLEX, a dynamic and innovative player in the portable power industry, has launched its ...
Virtual signaling
China Daily· 22 小時前As the Joe Biden administration pushes ahead with its "Indo-Pacific" strategy, greater weight has been given to the Quad ...
Apparel makers cutting carbon emissions in green push
China Daily· 24 小時前China's textile and apparel makers have stepped up efforts to cut carbon emissions during manufacturing and processing, ...
HOKA's FlyLab Pop-Up Brings the Joyful World of HOKA Innovation to Australia
HYPEBEAST· 1 日前In many ways, HOKA has done more to revolutionise the way Australians move than any other athletic brand in the last decade ...
Book Review: ‘The Manicurist’s Daughter’ By Susan Lieu
Forbes· 1 日前Susan Lieu's recent memoir, The Manicurist's Daughter, is a powerful exploration of her own journey of losing her mother ...
Japanese Buddhist temple divides opinion over pop group and chats with maids
South China Morning Post· 1 日前The temple created official accounts on YouTube and X that included unique content such as ...
科濟藥業於Nature Medicine及ASCO年會呈列CT041研究成果
阿思達克財經網· 1 日前科濟藥業(02171)宣布,CT041(satricabtagene autoleucel,satri-cel,一種靶向Claudin18.2自體CA...
科濟藥業(02171.HK)於美國臨床腫瘤學會口頭報告CT041臨床試驗結果
AASTOCKS via Yahoo財經香港· 1 日前科濟藥業-B(02171.HK)公布,CT041(satricabtagene autoleucel,satri-cel,一種靶向Claudin18.2自體CAR-T細胞候選產品)由研究者發起的臨床試驗 ...
科濟藥業於Nature Medicine及ASCO年會呈列CT041研究成果
infocast via Yahoo財經香港· 1 日前CT041(satri-cel)用於治療Claudin18.2陽性實體瘤,主要治療胃癌╱食管胃結合部腺癌及胰腺癌。正在進行的試驗包括...